Starpharma granted fast track approval for VivaGel

Company News

by Jessica Amir

Starpharma Holdings Limited, (ASX:SPL) says the FDA has granted a fast track designation as well as a Qualified Infectious Disease Product designation, for its VivaGel product.

VivaGel is used for the treatment and prevention of bacterial vaginoisis in women.

Starpharma has estimated that the market relating to the treatment and prevention of this infection is worth in excess of US$1 billion.

The company says it’s a very positive commercial development which expedites the path to US market entry for VivaGel.

Starpharma posted a net loss of $22.7 million at 30 June 2016.
 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.